filename,topic_id,topic_keywords
001.txt,2,"key events, financial performance, detailed review, current expectations, strategic objectives, , , , , "
002.txt,2,"key events, financial performance, detailed review, current expectations, strategic objectives, , , , , "
003.txt,2,"key events, financial performance, detailed review, current expectations, strategic objectives, , , , , "
004.txt,-1,Outlier
005.txt,-1,Outlier
006.txt,2,"key events, financial performance, detailed review, current expectations, strategic objectives, , , , , "
007.txt,2,"key events, financial performance, detailed review, current expectations, strategic objectives, , , , , "
008.txt,-1,Outlier
009.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
010.txt,2,"key events, financial performance, detailed review, current expectations, strategic objectives, , , , , "
011.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
012.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
013.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
014.txt,-1,Outlier
015.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
016.txt,-1,Outlier
017.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
018.txt,-1,Outlier
019.txt,-1,Outlier
020.txt,-1,Outlier
021.txt,2,"key events, financial performance, detailed review, current expectations, strategic objectives, , , , , "
022.txt,-1,Outlier
023.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
024.txt,-1,Outlier
025.txt,-1,Outlier
026.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
027.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
028.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
029.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
030.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
031.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
032.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
033.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
034.txt,-1,Outlier
035.txt,2,"key events, financial performance, detailed review, current expectations, strategic objectives, , , , , "
036.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
037.txt,-1,Outlier
038.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
039.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
040.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
041.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
042.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
043.txt,-1,Outlier
044.txt,-1,Outlier
045.txt,-1,Outlier
046.txt,-1,Outlier
047.txt,-1,Outlier
048.txt,-1,Outlier
049.txt,2,"key events, financial performance, detailed review, current expectations, strategic objectives, , , , , "
050.txt,2,"key events, financial performance, detailed review, current expectations, strategic objectives, , , , , "
051.txt,-1,Outlier
052.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
053.txt,-1,Outlier
054.txt,-1,Outlier
055.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
056.txt,-1,Outlier
057.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
058.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
059.txt,-1,Outlier
060.txt,-1,Outlier
061.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
062.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
063.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
064.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
065.txt,2,"key events, financial performance, detailed review, current expectations, strategic objectives, , , , , "
066.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
067.txt,-1,Outlier
068.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
069.txt,-1,Outlier
070.txt,-1,Outlier
071.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
072.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
073.txt,-1,Outlier
074.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
075.txt,-1,Outlier
076.txt,-1,Outlier
077.txt,-1,Outlier
078.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
079.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
080.txt,-1,Outlier
081.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
082.txt,-1,Outlier
083.txt,-1,Outlier
084.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
085.txt,-1,Outlier
086.txt,-1,Outlier
087.txt,-1,Outlier
088.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
089.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
090.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
091.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
092.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
093.txt,-1,Outlier
094.txt,0,"primary endpoint, improved progression, regulatory submissions, free survival, complete response, significant improvement, superior efficacy, systemic therapy, severe plaque, next steps"
095.txt,2,"key events, financial performance, detailed review, current expectations, strategic objectives, , , , , "
096.txt,2,"key events, financial performance, detailed review, current expectations, strategic objectives, , , , , "
097.txt,1,"top line, new products, worldwide revenue, strategic objective, total operating, pharmaceutical business, international inventory, interesting combinations, gross margin, great fit"
098.txt,2,"key events, financial performance, detailed review, current expectations, strategic objectives, , , , , "
099.txt,-1,Outlier
